
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1272680/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	4.9	62
2	Genomeâ€Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Movement Disorders, 2021, 36, 424-433.	2.2	101
3	Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Clusterâ€Randomized Trial. Movement Disorders, 2021, 36, 143-151.	2.2	5
4	Spatial Covariance of Cholinergic Muscarinic <scp>M₁</scp> / <scp>M₄</scp> Receptors in Parkinson's Disease. Movement Disorders, 2021, 36, 1879-1888.	2.2	5
5	Trajectories of pain over 6Âyears in early Parkinson's disease: ICICLE-PD. Journal of Neurology, 2021, 268, 4759-4767.	1.8	4
6	Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. Journal of Parkinson's Disease, 2021, 11, 1297-1308.	1.5	11
7	Altered network stability in progressive supranuclear palsy. Neurobiology of Aging, 2021, 107, 109-117.	1.5	8
8	Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease. Movement Disorders, 2021, 36, 611-621.	2.2	25
9	Development of a Disease Progression Model for Leucineâ€Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs. Clinical Pharmacology and Therapeutics, 2020, 107, 553-562.	2.3	13
10	New evidence on the management of Lewy body dementia. Lancet Neurology, The, 2020, 19, 157-169.	4.9	167
11	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	4.5	94
12	Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study. Journal of Parkinson's Disease, 2020, 10, 193-206.	1.5	34
13	Identifying delirium in Parkinson disease: A pilot study. International Journal of Geriatric Psychiatry, 2020, 35, 547-552.	1.3	14
14	Unacylated-Ghrelin Impairs Hippocampal Neurogenesis and Memory in Mice and Is Altered in Parkinson's Dementia in Humans. Cell Reports Medicine, 2020, 1, 100120.	3.3	15
15	Gait Progression Over 6 Years in Parkinson's Disease: Effects of Age, Medication, and Pathology. Frontiers in Aging Neuroscience, 2020, 12, 577435.	1.7	41
16	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. Parkinsonism and Related Disorders, 2020, 76, 49-53.	1.1	13
17	Impact of the <scp>COVID</scp> â€19 Pandemic on Parkinson's Disease and Movement Disorders. Movement Disorders Clinical Practice, 2020, 7, 357-360.	0.8	37
18	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	2.5	45

#	Article	IF	CITATIONS
19	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. Brain Stimulation, 2020, 13, 1031-1039.	0.7	39
20	Fluctuating cognition in the Lewy body dementias. Brain, 2019, 142, 3338-3350.	3.7	27
21	Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. Brain, 2019, 142, 2828-2844.	3.7	62
22	Proâ€Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLEâ€PD. Movement Disorders, 2019, 34, 1690-1698.	2.2	24
23	Prevalence and duration of nonâ€motor symptoms in prodromal Parkinson's disease. European Journal of Neurology, 2019, 26, 979-985.	1.7	73
24	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. Parkinsonism and Related Disorders, 2019, 65, 55-61.	1.1	14
25	Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2019, 34, 1244-1250.	1.3	31
26	Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 351-359.	1.5	28
27	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	1.1	7
28	Risk of Parkinson's disease dementia related to level I MDS PDâ€MCI. Movement Disorders, 2019, 34, 430-435.	2.2	32
29	Defining delirium in idiopathic Parkinson's disease: A systematic review. Parkinsonism and Related Disorders, 2019, 64, 29-39.	1.1	22
30	A randomized, doubleâ€blind, placeboâ€controlled trial of camicinal in Parkinson's disease. Movement Disorders, 2018, 33, 329-332.	2.2	14
31	Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study. Journal of Neurology, 2018, 265, 1528-1539.	1.8	35
32	Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease. Journal of Parkinson's Disease, 2018, 8, 511-515.	1.5	5
33	Detecting Mild Cognitive Deficits in <scp>P</scp> arkinson's <scp>D</scp> isease: <scp>C</scp> omparison of <scp>N</scp> europsychological <scp>T</scp> ests. Movement Disorders, 2018, 33, 1750-1759.	2.2	42
34	Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The <scp>DIAMOND</scp> Lewy study. International Journal of Geriatric Psychiatry, 2018, 33, 1293-1304.	1.3	31
35	Categorising Visual Hallucinations in Early Parkinson's Disease. Journal of Parkinson's Disease, 2018, 8, 447-453.	1.5	10
36	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. PLoS ONE, 2018. 13. e0201964.	1.1	33

#	Article	IF	CITATIONS
37	Intra―and interâ€network functional alterations in <scp>P</scp> arkinson's disease with mild cognitive impairment. Human Brain Mapping, 2017, 38, 1702-1715.	1.9	49
38	metabolic profiling of Parkinson's disease and mild cognitive impairment. Movement Disorders, 2017, 32, 927-932.	2.2	58
39	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. Parkinsonism and Related Disorders, 2017, 40, 40-46.	1.1	15
40	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Movement Disorders, 2017, 32, 1056-1065.	2.2	117
41	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. Neurobiology of Aging, 2017, 55, 78-90.	1.5	48
42	Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease. Cortex, 2017, 92, 8-18.	1.1	32
43	Cognitive impairment in Parkinson's disease: impact on quality of life of carers. International Journal of Geriatric Psychiatry, 2017, 32, 1362-1370.	1.3	41
44	Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. Parkinsonism and Related Disorders, 2017, 36, 63-68.	1.1	50
45	Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. International Journal of Geriatric Psychiatry, 2017, 32, 1280-1304.	1.3	39
46	Natural history of falls in an incident cohort of Parkinson's disease: early evolution, risk and protective features. Journal of Neurology, 2017, 264, 2268-2276.	1.8	42
47	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	2.2	608
48	Utility and accuracy of perceptual voice and speech distinctions in the diagnosis of Parkinson's disease, PSP and MSA-P. Neurodegenerative Disease Management, 2017, 7, 191-203.	1.2	25
49	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. Movement Disorders Clinical Practice, 2017, 4, 509-516.	0.8	35
50	Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy. Parkinsonism and Related Disorders, 2017, 34, 7-14.	1.1	44
51	Lower urinary tract symptoms in Parkinson's disease: Prevalence, aetiology and management. Parkinsonism and Related Disorders, 2017, 35, 8-16.	1.1	88
52	Poor Sleep Quality and Progression of Gait Impairment in an Incident Parkinson's Disease Cohort. Journal of Parkinson's Disease, 2017, 7, 465-470.	1.5	20
53	The Role of Vitamin D in Disease Progression in Early Parkinson's Disease. Journal of Parkinson's Disease, 2017, 7, 669-675.	1.5	55
54	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLoS ONE, 2017, 12, e0175674.	1.1	110

#	Article	IF	CITATIONS
55	ABN News. Practical Neurology, 2017, 17, 84-84.	0.5	О
56	Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection. Journal of Parkinson's Disease, 2016, 6, 289-300.	1.5	21
57	Embarking on a research project…or research for the absolute novice. Journal of the Royal College of Physicians of Edinburgh, The, 2016, 46, 182-186.	0.2	Ο
58	An Unusual Cause of Falls in a Young Woman. Journal of the Royal College of Physicians of Edinburgh, The, 2016, 46, 160-162.	0.2	6
59	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. Frontiers in Aging Neuroscience, 2016, 8, 121.	1.7	16
60	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. Frontiers in Aging Neuroscience, 2016, 8, 147.	1.7	33
61	Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?. Movement Disorders, 2016, 31, 937-946.	2.2	99
62	Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis. Psychological Medicine, 2016, 46, 657-667.	2.7	49
63	Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. Parkinsonism and Related Disorders, 2016, 27, 47-53.	1.1	133
64	Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease. JAMA Neurology, 2016, 73, 668.	4.5	69
65	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 33, 96-101.	1.1	46
66	Spectrum of Movement Disorders in Mitochondrial Disorders–Reply. JAMA Neurology, 2016, 73, 1254.	4.5	0
67	Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2016, 31, 765-770.	1.3	12
68	Gray and white matter imaging: <scp>A</scp> biomarker for cognitive impairment in early <scp>P</scp> arkinson's disease?. Movement Disorders, 2016, 31, 103-110.	2.2	129
69	<scp>S</scp> erum immune markers and disease progression in an incident <scp>P</scp> arkinson's disease cohort (<scp>ICICLEâ€PD</scp>). Movement Disorders, 2016, 31, 995-1003.	2.2	211
70	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Movement Disorders, 2016, 31, 1062-1066.	2.2	59
71	The effects of cognitive reserve and lifestyle on cognition and dementia in Parkinson's disease—a longitudinal cohort study. International Journal of Geriatric Psychiatry, 2016, 31, 13-23.	1.3	63
72	Neural correlates of attentionâ€executive dysfunction in lewy body dementia and Alzheimer's disease. Human Brain Mapping, 2016, 37, 1254-1270.	1.9	49

#	Article	IF	CITATIONS
73	Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naÃ⁻ve cohort. Movement Disorders, 2016, 31, 1829-1836.	2.2	87
74	Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. Movement Disorders, 2016, 31, 1518-1526.	2.2	128
75	Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease. Movement Disorders, 2016, 31, 1923-1924.	2.2	3
76	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. Movement Disorders, 2016, 31, 668-675.	2.2	31
77	Olfaction in <i>Parkin</i> single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. Acta Neurologica Scandinavica, 2016, 134, 271-276.	1.0	21
78	Visual Hallucinations in Eye Disease and Lewy Body Disease. American Journal of Geriatric Psychiatry, 2016, 24, 350-358.	0.6	21
79	Exome sequencing in dementia with Lewy bodies. Translational Psychiatry, 2016, 6, e728-e728.	2.4	35
80	Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease. Neuroscience and Biobehavioral Reviews, 2016, 64, 326-345.	2.9	216
81	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	2.6	333
82	Dementia with Lewy bodies: The emerging role of primary care. European Journal of General Practice, 2016, 22, 53-57.	0.9	2
83	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). Quality of Life Research, 2016, 25, 81-88.	1.5	20
84	Accumulation of dipeptide repeat proteins predates that of <scp>TDP</scp> â€43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in <scp><i>C9ORF72</i></scp> gene. Neuropathology and Applied Neurobiology, 2015, 41, 601-612.	1.8	62
85	Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for earlyâ€stage Parkinson's disease. Annals of Neurology, 2015, 78, 1000-1004.	2.8	106
86	Tracking Parkinson's: Study Design and Baseline Patient Data. Journal of Parkinson's Disease, 2015, 5, 947-959.	1.5	64
87	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson's Disease?. Journal of Parkinson's Disease, 2015, 5, 743-747.	1.5	17
88	Precompetitive Data Sharing as a Catalyst toÂAddress Unmet Needs in Parkinson's Disease 1. Journal of Parkinson's Disease, 2015, 5, 581-594.	1.5	25
89	Adultâ€onset myoclonus ataxia associated with the mitochondrial m.8993 <scp>T</scp> > <scp>C</scp> " <scp>NARP</scp> ―mutation. Movement Disorders, 2015, 30, 1432-1433.	2.2	3
90	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD. Neuroepidemiology, 2015, 45, 282-297.	1.1	23

#	Article	IF	CITATIONS
91	Patient and Informant Views on Visual Hallucinations in Parkinson Disease. American Journal of Geriatric Psychiatry, 2015, 23, 970-976.	0.6	7
92	Progression of gait dysfunction in incident Parkinson's disease: Impact of medication and phenotype. Movement Disorders, 2015, 30, 359-367.	2.2	168
93	Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain, 2015, 138, 2974-2986.	3.7	188
94	The relationship between real world ambulatory activity and falls in incident Parkinson's disease: Influence of classification scheme. Parkinsonism and Related Disorders, 2015, 21, 236-242.	1.1	59
95	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders, 2015, 30, 919-927.	2.2	244
96	Variation in complement protein C1q is not a major contributor to cognitive impairment in Parkinson's disease. Neuroscience Letters, 2015, 594, 66-69.	1.0	11
97	UK Parkinson's Excellence Network: empowering service improvement across the UK. Neurodegenerative Disease Management, 2015, 5, 173-176.	1.2	2
98	UK Parkinson's Excellence Network: time for a paradigm shift in Parkinson's care. Neurodegenerative Disease Management, 2015, 5, 177-180.	1.2	0
99	Quality of Life and Mild Cognitive Impairment in Early Parkinson's Disease: Does Subtype Matter?. Journal of Parkinson's Disease, 2015, 4, 331-336.	1.5	22
100	Semantic profiles in mild cognitive impairment associated with Alzheimer?s and Parkinson?s diseases. Functional Neurology, 2015, 30, 113-8.	1.3	7
101	Cognition and Gait Show a Selective Pattern of Association Dominated by Phenotype in Incident Parkinsonââ,¬â"¢s Disease. Frontiers in Aging Neuroscience, 2014, 6, 249.	1.7	73
102	The association between retirement and age on physical activity in older adults. Age and Ageing, 2014, 43, 386-393.	0.7	76
103	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain, 2014, 137, 2743-2758.	3.7	127
104	Primary sleep disorder prevalence in patients with newly diagnosed Parkinson's disease. Movement Disorders, 2014, 29, 259-262.	2.2	37
105	Healthâ€related quality of life in early Parkinson's disease: The impact of nonmotor symptoms. Movement Disorders, 2014, 29, 195-202.	2.2	292
106	Cognition in movement disorders: Where can we hope to be in ten years?. Movement Disorders, 2014, 29, 704-711.	2.2	15
107	Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism and Related Disorders, 2014, 20, 1071-1075.	1.1	110
108	The incidence of Parkinson's disease in the North-East of England. Age and Ageing, 2014, 43, 257-263.	0.7	22

#	Article	IF	CITATIONS
109	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. Clinical Neuropharmacology, 2014, 37, 9-16.	0.2	62
110	Delayed gastric emptying in Parkinson's disease. Movement Disorders, 2014, 29, 23-32.	2.2	124
111	Thinking positively about chronic illness: An exploration of optimism, illness perceptions and wellâ€being in patients with <scp>P</scp> arkinson's disease. British Journal of Health Psychology, 2014, 19, 363-379.	1.9	57
112	The basal ganglia in perceptual timing: Timing performance in Multiple System Atrophy and Huntington's disease. Neuropsychologia, 2014, 52, 73-81.	0.7	74
113	A phase 2 trial of the GSKâ€3 inhibitor tideglusib in progressive supranuclear palsy. Movement Disorders, 2014, 29, 470-478.	2.2	251
114	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Movement Disorders, 2014, 29, 857-867.	2.2	193
115	Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 452-455.	1.1	38
116	Visual complaints and visual hallucinations in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 318-322.	1.1	73
117	The expanding universe of disorders of the basal ganglia. Lancet, The, 2014, 384, 523-531.	6.3	155
118	The nature of dual-task interference during gait in incident Parkinson's disease. Neuroscience, 2014, 265, 83-94.	1.1	147
119	Subthalamic deep brain stimulation in Parkinson׳s disease has no significant effect on perceptual timing in the hundreds of milliseconds range. Neuropsychologia, 2014, 57, 29-37.	0.7	10
120	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	4.9	245
121	Motor Phenotypes, Medication and Mood: Further Associations with Impulsive Behaviours in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 245-254.	1.5	16
122	Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. Journal of Parkinson's Disease, 2014, 4, 131-137.	1.5	50
123	Ambulatory activity in incident Parkinson's: more than meets the eye?. Journal of Neurology, 2013, 260, 2964-2972.	1.8	140
124	Thyrotoxic Periodic Paralysis: Correct Hypokalemia with Caution. Journal of Emergency Medicine, 2013, 45, 338-340.	0.3	11
125	Mild cognitive impairment in Parkinson's disease. Age and Ageing, 2013, 42, 567-576.	0.7	103
126	Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. Journal of Parkinson's Disease, 2013, 3, 1-11.	1.5	79

#	Article	IF	CITATIONS
127	Summary of the recommendations of the <scp>EFNS</scp> / <scp>MDS</scp> â€ <scp>ES</scp> review on therapeutic management of <scp>P</scp> arkinson's disease. European Journal of Neurology, 2013, 20, 5-15.	1.7	290
128	<scp>EFNS</scp> / <scp>MDS</scp> â€ <scp>ES</scp> recommendations for the diagnosis of <scp>P</scp> arkinson's disease. European Journal of Neurology, 2013, 20, 16-34.	1.7	460
129	Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 339-345.	4.9	118
130	Short latency afferent inhibition: A biomarker for mild cognitive impairment in Parkinson's disease?. Movement Disorders, 2013, 28, 1285-1288.	2.2	56
131	Magnetic resonance imaging: A biomarker for cognitive impairment in Parkinson's disease?. Movement Disorders, 2013, 28, 425-438.	2.2	81
132	Mild cognitive impairment in Parkinson's disease: millstone or milestone?. Practical Neurology, 2013, 13, 68-69.	0.5	12
133	Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4â€year study. International Journal of Geriatric Psychiatry, 2013, 28, 626-631.	1.3	97
134	New horizons in the pathogenesis, assessment and management of movement disorders. Age and Ageing, 2013, 42, 2-10.	0.7	7
135	Visual exploration in Parkinson's disease and Parkinson's disease dementia. Brain, 2013, 136, 739-750.	3.7	72
136	How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale. Movement Disorders, 2013, 28, 668-670.	2.2	622
137	Guided Self-Help for the Management of Worry in Parkinson's Disease: A Pilot Study. Journal of Parkinson's Disease, 2013, 3, 61-68.	1.5	18
138	Mild depressive symptoms are associated with gait impairment in early Parkinson's disease. Movement Disorders, 2013, 28, 634-639.	2.2	38
139	Rapid eye movement sleep behavior disorder in Parkinson's disease: Magnetic resonance imaging study. Movement Disorders, 2013, 28, 832-836.	2.2	52
140	Amantadine-induced myoclonus in a patient with progressive supranuclear palsy. Age and Ageing, 2012, 41, 695-696.	0.7	14
141	Cognition, coping, and outcome in Parkinson's disease. International Psychogeriatrics, 2012, 24, 1656-1663.	0.6	41
142	Falling short: Underestimation of fracture risk in atypical parkinsonian syndromes. Parkinsonism and Related Disorders, 2012, 18, 692-693.	1.1	4
143	Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain, 2012, 135, 2779-2788.	3.7	187
144	Systematic Review and UKâ€Based Study of <i>PARK2 (parkin), PINK1, PARK7 (DJâ€1)</i> and <i>LRRK2</i> in earlyâ€onset Parkinson's disease. Movement Disorders, 2012, 27, 1522-1529.	2.2	141

#	Article	IF	CITATIONS
145	Visual sampling during walking in people with Parkinson's disease and the influence of environment and dual-task. Brain Research, 2012, 1473, 35-43.	1.1	42
146	Dorsal rather than ventral visual pathways discriminate freezing status in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 1094-1096.	1.1	18
147	Frontotemporal Dementia in Elderly Individuals. Archives of Neurology, 2012, 69, 1052.	4.9	46
148	To sleep, perchance to dement: RBD and cognitive decline in Parkinson's disease. Movement Disorders, 2012, 27, 671-673.	2.2	6
149	Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2012, 27, 1754-1762.	2.2	163
150	Identifying prodromal Parkinson's disease: Preâ€Motor disorders in Parkinson's disease. Movement Disorders, 2012, 27, 617-626.	2.2	443
151	Understanding the impact of deep brain stimulation on ambulatory activity in advanced Parkinson's disease. Journal of Neurology, 2012, 259, 1081-1086.	1.8	58
152	Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease?. Movement Disorders, 2012, 27, 236-241.	2.2	116
153	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Movement Disorders, 2012, 27, 312-315.	2.2	56
154	Parkinson's disease motor subtypes and mood. Movement Disorders, 2012, 27, 379-386.	2.2	114
155	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: <i>Movement</i> Disorder Society Task Force guidelines. Movement Disorders, 2012, 27, 349-356.	2.2	1,908
156	Synaptic Protein Alterations in Parkinson's Disease. Molecular Neurobiology, 2012, 45, 126-143.	1.9	27
157	Retinal thickness in Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 431-436.	1.1	107
158	Pathological correlates of frontotemporal lobar degeneration in the elderly. Acta Neuropathologica, 2011, 121, 365-371.	3.9	70
159	Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction?. Journal of Neurology, 2011, 258, 566-572.	1.8	105
160	Targeting dopaâ€sensitive and dopaâ€resistant gait dysfunction in Parkinson's disease: Selective responses to internal and external cues. Movement Disorders, 2011, 26, 430-435.	2.2	72
161	Parkinson's disease: The quintessential neuropsychiatric disorder. Movement Disorders, 2011, 26, 1022-1031.	2.2	349
162	Visual symptoms in Parkinson's disease and Parkinson's disease dementia. Movement Disorders, 2011, 26, 2387-2395.	2.2	164

#	Article	IF	CITATIONS
163	Commentary on the postencephalitic cases of Dr. Kinnier Wilson. Movement Disorders, 2011, 26, 2460-2461.	2.2	0
164	Cognitive impairment in nondemented Parkinson's disease. Movement Disorders, 2011, 26, 2483-2495.	2.2	115
165	The interplay of cholinergic function, attention, and falls in Parkinson's disease. Movement Disorders, 2011, 26, 2496-2503.	2.2	193
166	Coping in Parkinson's disease: an examination of the coping inventory for stressful situations. International Journal of Geriatric Psychiatry, 2011, 26, 1030-1037.	1.3	24
167	Hyperthyroid chorea. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 279-286.	1.0	7
168	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Human Molecular Genetics, 2011, 20, 345-353.	1.4	202
169	Factors predicting discharge of Huntington's disease patients from a neuropsychiatry unit. International Psychogeriatrics, 2010, 22, 489-492.	0.6	3
170	Fall in circulating mononuclear cell mitochondrial DNA content in human sepsis. Intensive Care Medicine, 2010, 36, 956-962.	3.9	62
171	Parkinson's Disease Dementia. Current Neurology and Neuroscience Reports, 2010, 10, 292-298.	2.0	18
172	Hyposmia in progressive supranuclear palsy. Movement Disorders, 2010, 25, 570-577.	2.2	43
173	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2010, 25, 1077-1081.	2.2	106
174	The pattern of habitual sedentary behavior is different in advanced Parkinson's disease. Movement Disorders, 2010, 25, 2114-2120.	2.2	71
175	The Treatment of Cognitive Impairment Associated with Parkinson's Disease. Brain Pathology, 2010, 20, 672-678.	2.1	17
176	The clinical approach to movement disorders. Nature Reviews Neurology, 2010, 6, 29-37.	4.9	166
177	Genetic variation of CHRNA4 does not modulate attention in Parkinson's disease. Neuroscience Letters, 2010, 479, 123-125.	1.0	6
178	Executive dysfunction and attention contribute to gait interference in â€~off' state Parkinson's Disease. Gait and Posture, 2010, 31, 169-174.	0.6	112
179	Two in the hand, an essential lesson in tremor management. Practical Neurology, 2010, 10, 160-163.	0.5	0
180	The retina in Parkinson's disease. Brain, 2009, 132, 1128-1145.	3.7	327

#	Article	IF	CITATIONS
181	Detecting new neurodegenerative disease genes: does phenotype accuracy limit the horizon?. Trends in Genetics, 2009, 25, 486-488.	2.9	17
182	Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3â€year European multicenter study with repeat [¹²³ 1]FPâ€CIT SPECT. Movement Disorders, 2009, 24, 500-508.	2.2	195
183	No association between common <i>POLG1</i> variants and sporadic idiopathic Parkinson's disease. Movement Disorders, 2009, 24, 1092-1094.	2.2	32
184	Levodopa use and sleep in patients with dementia with Lewy bodies. Movement Disorders, 2009, 24, 609-612.	2.2	11
185	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. European Journal of Neurology, 2009, 16, 297-309.	1.7	170
186	Impaired attention predicts falling in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 110-115.	1.1	179
187	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Human Genetics, 2008, 124, 95-99.	1.8	34
188	Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: Contrast with other dementias. Journal of Chemical Neuroanatomy, 2008, 35, 268-274.	1.0	6
189	How do I sound to me? Perceived changes in communication in Parkinson's disease. Clinical Rehabilitation, 2008, 22, 14-22.	1.0	103
190	Clinical assessment of progressive supranuclear palsy over time: new rating scale validated. Nature Clinical Practice Neurology, 2007, 3, 600-601.	2.7	4
191	Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2007, 23, 161-167.	0.7	51
192	Muscarinic Receptors in the Thalamus in Progressive Supranuclear Palsy and Other Neurodegenerative Disorders. Journal of Neuropathology and Experimental Neurology, 2007, 66, 399-404.	0.9	13
193	Tau and αâ€synuclein in susceptibility to, and dementia in, Parkinson's disease. Annals of Neurology, 2007, 62, 145-153.	2.8	256
194	Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Movement Disorders, 2007, 22, 55-61.	2.2	100
195	Predicting the cost of Parkinson's disease. Movement Disorders, 2007, 22, 804-812.	2.2	70
196	Rotigotine transdermal patch in early Parkinson's disease: A randomized, doubleâ€blind, controlled study versus placebo and ropinirole. Movement Disorders, 2007, 22, 2398-2404.	2.2	214
197	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Movement Disorders, 2007, 22, 2314-2324.	2.2	885
198	Towards an EMG-Controlled Prosthetic Hand Using a 3-D Electromagnetic Positioning System. IEEE Transactions on Instrumentation and Measurement, 2007, 56, 178-186.	2.4	53

#	Article	IF	CITATIONS
199	In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. NeuroImage, 2006, 33, 423-429.	2.1	54
200	Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies. American Journal of Geriatric Psychiatry, 2006, 14, 153-160.	0.6	153
201	More Severe Functional Impairment in Dementia With Lewy Bodies Than Alzheimer Disease Is Related to Extrapyramidal Motor Dysfunction. American Journal of Geriatric Psychiatry, 2006, 14, 582-588.	0.6	65
202	Progression of White Matter Hyperintensities in Alzheimer Disease, Dementia With Lewy Bodies, and Parkinson Disease Dementia: A Comparison With Normal Aging. American Journal of Geriatric Psychiatry, 2006, 14, 842-849.	0.6	108
203	Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson's disease. Parkinsonism and Related Disorders, 2006, 12, 139-141.	1.1	37
204	Cortical Lewy body disease and Parkinson's disease dementia. Current Opinion in Neurology, 2006, 19, 572-579.	1.8	49
205	Characterizing behavioral and cognitive dysexecutive changes in progressive supranuclear palsy. Movement Disorders, 2006, 21, 199-207.	2.2	61
206	Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. Movement Disorders, 2006, 21, 148-158.	2.2	312
207	Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease. Archives of Neurology, 2006, 63, 826.	4.9	147
208	Life with communication changes in Parkinson's disease. Age and Ageing, 2006, 35, 235-239.	0.7	254
209	Hard to swallow: dysphagia in Parkinson's disease. Age and Ageing, 2006, 35, 614-618.	0.7	198
210	Prevalence and Severity of Gait Disorders in Alzheimer's and Nonâ€Alzheimer's Dementias. Journal of the American Geriatrics Society, 2005, 53, 1681-1687.	1.3	214
211	Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Research - Neuroimaging, 2005, 139, 79-88.	0.9	60
212	Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Annals of Neurology, 2005, 57, 564-567.	2.8	178
213	Commentary on: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP–parkinsonism, by D. Williams, R. de Silva, D. Paviour, et al. (Brain-2004-01045.R1). Brain, 2005, 128, 1235-1236.	3.7	3
214	Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2005, 20, 776-782.	1.3	36
215	Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies. Brain, 2005, 128, 1267-1276.	3.7	201
216	Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain, 2004, 127, 791-800.	3.7	544

#	Article	IF	CITATIONS
217	Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies. Archives of Neurology, 2004, 61, 919.	4.9	312
218	Neuropsychiatric Complications of Medical and Surgical Therapies for Parkinson's Disease. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 172-180.	1.2	102
219	Cholinergic systems in progressive supranuclear palsy. Brain, 2004, 128, 239-249.	3.7	69
220	The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. NeuroImage, 2004, 23, 956-966.	2.1	58
221	3-D motion system ("data-gloves"): application for Parkinson's disease. IEEE Transactions on Instrumentation and Measurement, 2003, 52, 662-674.	2.4	55
222	Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Annals of Neurology, 2003, 54, 235-238.	2.8	204
223	MRI Study of Caudate Nucleus Volume in Parkinson's Disease with and without Dementia with Lewy Bodies and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2003, 16, 57-63.	0.7	88
224	Regional cerebral blood flow in Parkinson's disease with and without dementia. NeuroImage, 2003, 20, 1309-1319.	2.1	136
225	Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. Neuroscience Letters, 2003, 341, 177-180.	1.0	81
226	Systematic Review and Meta-Analysis Show that Dementia with Lewy Bodies Is a Visual-Perceptual and Attentional-Executive Dementia. Dementia and Geriatric Cognitive Disorders, 2003, 16, 229-237.	0.7	206
227	Dementia with Lewy bodies. Seminars in Clinical Neuropsychiatry, 2003, 8, 46-57.	1.9	124
228	Progressive supranuclear palsy: where are we now?. Lancet Neurology, The, 2002, 1, 359-369.	4.9	140
229	Late-onset axial jerky dystonia due to the DYT1 deletion. Movement Disorders, 2002, 17, 196-198.	2.2	86
230	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neuroscience Letters, 2001, 312, 118-120.	1.0	26
231	Distribution of cranial MRI abnormalities in patients with symptomatic and subclinical CADASIL British Journal of Radiology, 2000, 73, 256-265.	1.0	57
232	One Year Follow-Up of Parkinsonism in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2000, 11, 219-222.	0.7	44
233	The epidemiology of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome). Parkinsonism and Related Disorders, 2000, 6, 145-153.	1.1	16
234	SPECTRUM OF PARKINSON'S DISEASE, PARKINSON'S DEMENTIA, AND LEWY BODY DEMENTIA. Neurologic Clinics, 2000, 18, 865-883.	0.8	138

#	Article	IF	CITATIONS
235	Tardive diaphragmatic flutter. Movement Disorders, 1998, 13, 190-192.	2.2	21
236	New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet, The, 1997, 350, 903-907.	6.3	299
237	Striatal dopaminergic loss without parkinsonism in a case of corticobasal degeneration. Acta Neurologica Scandinavica, 1997, 95, 287-292.	1.0	5
238	Separating Parkinson's Disease From Normality. Archives of Neurology, 1994, 51, 237.	4.9	73
239	Is bed rest useful after diagnostic lumbar puncture?. Postgraduate Medical Journal, 1992, 68, 581-583.	0.9	35
240	Langerhans' cell histiocytosis and the nervous system. Journal of Neurology, 1992, 239, 345-350.	1.8	21
241	Strychnine poisoning as an unusual cause of convulsions. Postgraduate Medical Journal, 1989, 65, 563-564.	0.9	18